Takeda Pharmaceutical (TYO: 4502) has signed a strategic alliance to discover, develop and commercialize novel therapies for specialty gastrointestinal (GI) diseases using Canadian biotech firm enGene’s “Gene Pill” gene delivery platform.
The strategic alliance will leverage enGene’s expertise and intellectual property position in delivering therapeutic genes to cells of the gut lining by using its proprietary non-viral vector platform.
Under the terms of the agreement, enGene will develop up to two undisclosed targets selected by Takeda, Japan’s largest drugmaker, through preclinical proof of concept and Investigational New Drug (IND) enabling studies. At that point, Takeda will have an option to exclusively license the global rights for the product candidates.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze